Top Markets
#1 Black Phoenix Black Phoenix +21,376.82%
#2 Nesa Nesa +750.04%
#3 ADO Protocol ADO Protocol +101.88%
#4 Cortex Cortex +93.70%
#5 Ontology Gas Ontology Gas +69.25%
#6 Kinesis Silver Kinesis Silver +54.02%
#7 OpenEden OpenEden +26.38%
#8 Magma Finance Magma Finance +24.43%
#9 PondCoin PondCoin +24.08%
#10 QuantixAI QuantixAI +23.16%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Flerie AB (publ) Flerie AB (publ)

Flerie AB (publ)

FLERIE
Rank in Stocks #18881
Flerie AB (publ) functions as a venture capital entity, concentrating its... Flerie AB (publ) functions as a venture capital entity, concentrating its investments on nascent businesses. The firm actively seeks to fund biotechnology and pharmaceutical companies dedicated to advancing drug discovery and development, or producing innovative tools and applications aimed at addressing pressing global health concerns. Geographically, their investment scope includes Europe, the United States, and Israel. Founded in 2011, Flerie AB (publ) is headquartered in Stockholm, Sweden, and also operates a branch office in London, United Kingdom.
Share Price
$2.11
Market Cap
$183.02M
Change (1 day)
-1.82%
Change (1 year)
-45.27%
Country
SE
Trade Flerie AB (publ) (FLERIE)

Category

Healthcare
Revenue for Flerie AB (publ) (FLERIE)
Revenue in Aug 2026 TTM: 0
According to Flerie AB (publ) latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Flerie AB (publ) from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
 $79.67B -
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
 $97.93B -
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
 $64.39B -
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
 $77.52B -
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
 $66.40B -
US